Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 45: 1881-1882, 1999;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Web of Science (4)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tredger, J. M.
Right arrow Articles by Gonde, C. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tredger, J. M.
Right arrow Articles by Gonde, C. E.
Related Collections
Right arrow Drug Monitoring and Toxicology
(Clinical Chemistry. 1999;45:1881-1882.)
© 1999 American Association for Clinical Chemistry, Inc.

Letters

Performance of the IMx Tacrolimus II Assay and Practical Limits of Detection

J. Michael Tredgera, Colleen D. Gilkes and Christopher E. Gonde

Institute of Liver Studies, King's College Hospital, and School of Medicine, Denmark Hill, London SE5 9RS, UK
a Address correspondence to this author at: Institute of Liver Studies, Guy's, King's, St. Thomas' School of Medicine at Denmark Hill, Bessemer Road, London SE5 9PJ, UK. Fax 44-171-346-3760; e-mail michael.tredger@kcl.ac.uk.


To The Editor:

Recent correspondence to Clinical Chemistry (1)(2) addressed the performance of the second generation Tacrolimus assay for the IMx analyzer (Abbott Diagnostics), with the former letter identifying nonequivalence in results from its predecessor and the latter considering performance approaching the lower limits of detection. Our own published results (3) have considered these points, and we report here our additional experience.

In their comparison of the second- vs the first-generation assays, Garg et al. (1) described comparable coefficients of variation (CVs), but this is not the case when identical control samples are used in each assay at low concentrations (<=5 µg/L), e.g., 14.2% vs 42.4% at 4.2 µg of tacrolimus per liter of blood (1). In common with previous findings (3)(4)(5), Garg et al. (1) reported lower values with the second-generation assay using 36 samples of undefined origin. The slopes and intercepts reported for these various comparisons differed (as did the comparison methods applied), but Garg . . . [Full Text of this Article]


References






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1999 by the American Association for Clinical Chemistry.